Lim Chang Sup, Moon Won, Park Seun Ja, Park Moo In, Kim Hyung Hun, Kim Jong Bin, Choi Jeong Moon, Chang Hee Kyung, Lee Seung Hyun
Departments of Internal Medicine, Pathology, and Surgery, Institute for Medical Science, Kosin University College of Medicine, Busan, Korea.
Korean J Gastroenterol. 2013 Sep;62(3):169-73. doi: 10.4166/kjg.2013.62.3.169.
Crohn's disease is characterized by chronic transmural inflammation of the bowel and is associated with serious complications, such as bowel strictures, abscesses, fistula formation, and perforation. As neither medical nor surgical therapy provides a cure for Crohn's disease, the primary goals of therapy are to induce and maintain remission and prevent complications. As a biologic agent, infliximab, a monoclonal antibody to tumor necrosis factor, is indicated for refractory luminal and fistulizing Crohn's disease that does not respond to other medical therapies or surgery. Infliximab has proven to be very effective for inducing and maintaining remission in Crohn's disease; however, infliximab treatment has several potential complications. Here, we report a case of free perforation following a therapeutic response after an initial dose of infliximab for Crohn's disease. This is the first case report describing a free perforation in a Crohn's disease patient after an initial dose of infliximab.
克罗恩病的特征是肠道的慢性透壁性炎症,并伴有严重并发症,如肠道狭窄、脓肿、瘘管形成和穿孔。由于药物治疗和手术治疗均无法治愈克罗恩病,治疗的主要目标是诱导并维持病情缓解以及预防并发症。作为一种生物制剂,英夫利昔单抗是一种肿瘤坏死因子单克隆抗体,适用于对其他药物治疗或手术无反应的难治性管腔型和瘘管型克罗恩病。英夫利昔单抗已被证明对诱导和维持克罗恩病的缓解非常有效;然而,英夫利昔单抗治疗有几种潜在并发症。在此,我们报告1例克罗恩病患者在首剂英夫利昔单抗治疗取得疗效后发生游离穿孔的病例。这是首例描述克罗恩病患者首剂英夫利昔单抗治疗后发生游离穿孔的病例报告。